Sobreprecio y acceso a los medicamentos: el caso de los medicamentos esenciales en México
Autor(a) principal: | |
---|---|
Data de Publicação: | 1998 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | spa |
Título da fonte: | Cadernos de Saúde Pública |
Texto Completo: | https://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/996 |
Resumo: | Accessibility and availability of drugs has been a matter of great concern for health services all over the world, especially for less developed countries. The World Health Organization has devoted considerable time to this matter. Although the essential drug policy has been well-accepted by health agencies and NGOs, the pharmaceutical industry has not proven willing to produce essential drugs at affordable prices. The purpose of this study is to examine price levels of essential drugs in Mexico. The evaluation was performed through a comparison of international and national prices for leading drugs in the respective therapeutic categories and included in the WHO model list of essential drugs. The study shows clearly that prices of essential brand-name drugs in Mexico are very high. Per capita consumption has remained stable despite a sharp decrease in the Mexican GDP since 1995. The article discusses the reasons for this and proposes measures to deal with the problem. |
id |
FIOCRUZ-5_3d86de7826e94d2b6d6bb99524d12432 |
---|---|
oai_identifier_str |
oai:ojs.teste-cadernos.ensp.fiocruz.br:article/996 |
network_acronym_str |
FIOCRUZ-5 |
network_name_str |
Cadernos de Saúde Pública |
repository_id_str |
|
spelling |
Sobreprecio y acceso a los medicamentos: el caso de los medicamentos esenciales en MéxicoMedicamentos EsencialesPrecios de MedicamentosPolíticas de SaludAccessibility and availability of drugs has been a matter of great concern for health services all over the world, especially for less developed countries. The World Health Organization has devoted considerable time to this matter. Although the essential drug policy has been well-accepted by health agencies and NGOs, the pharmaceutical industry has not proven willing to produce essential drugs at affordable prices. The purpose of this study is to examine price levels of essential drugs in Mexico. The evaluation was performed through a comparison of international and national prices for leading drugs in the respective therapeutic categories and included in the WHO model list of essential drugs. The study shows clearly that prices of essential brand-name drugs in Mexico are very high. Per capita consumption has remained stable despite a sharp decrease in the Mexican GDP since 1995. The article discusses the reasons for this and proposes measures to deal with the problem.Para la Organización Mundial de la Salud (OMS) la accesibilidad y la disponibilidad de los medicamentos es un tema central al cual le ha dedicado una gran atención. Si bien la política de medicamentos esenciales ha tenido una acogida favorable por parte de las organizaciones sanitarias, la industria farmacéutica, especialmente sus filiales asentadas en los países menos desarrollados, no ha brindado una respuesta adecuada a los planteamientos de la OMS de proporcionar medicamentos esenciales a precios accesibles. El objetivo de este trabajo es estudiar el precio de los medicamentos esenciales de marca en México en relación al precio de los medicamentos esenciales genéricos disponibles en el mercado internacional. Se estudió una muestra de especialidades farmacéuticas líderes de ventas en su categoría terapéutica y se compararon los precios, por unidades farmacéuticas, de los medicamentos de marca y los medicamentos genéricos a precio internacional. Los resultados muestran que el nivel de precios de los medicamentos esenciales en México es muy elevado. La venta per cápita no se ha reducido, a pesar de la caída del producto interno bruto que se produjo en México a partir del año de 1995. Se discuten las razones de este sobreprecio y se proponen algunas medidas para solucionar este problema.Reports in Public HealthCadernos de Saúde Pública1998-07-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlapplication/pdfhttps://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/996Reports in Public Health; Vol. 14 No. 3 (1998): July/SeptemberCadernos de Saúde Pública; v. 14 n. 3 (1998): Julho/Setembro1678-44640102-311Xreponame:Cadernos de Saúde Públicainstname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZspahttps://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/996/1982https://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/996/1983Molina-Salazar, Raúl E.Rivas-Vilchis, José F.info:eu-repo/semantics/openAccess2024-03-06T15:26:10Zoai:ojs.teste-cadernos.ensp.fiocruz.br:article/996Revistahttps://cadernos.ensp.fiocruz.br/ojs/index.php/csphttps://cadernos.ensp.fiocruz.br/ojs/index.php/csp/oaicadernos@ensp.fiocruz.br||cadernos@ensp.fiocruz.br1678-44640102-311Xopendoar:2024-03-06T13:01:12.907392Cadernos de Saúde Pública - Fundação Oswaldo Cruz (FIOCRUZ)true |
dc.title.none.fl_str_mv |
Sobreprecio y acceso a los medicamentos: el caso de los medicamentos esenciales en México |
title |
Sobreprecio y acceso a los medicamentos: el caso de los medicamentos esenciales en México |
spellingShingle |
Sobreprecio y acceso a los medicamentos: el caso de los medicamentos esenciales en México Molina-Salazar, Raúl E. Medicamentos Esenciales Precios de Medicamentos Políticas de Salud |
title_short |
Sobreprecio y acceso a los medicamentos: el caso de los medicamentos esenciales en México |
title_full |
Sobreprecio y acceso a los medicamentos: el caso de los medicamentos esenciales en México |
title_fullStr |
Sobreprecio y acceso a los medicamentos: el caso de los medicamentos esenciales en México |
title_full_unstemmed |
Sobreprecio y acceso a los medicamentos: el caso de los medicamentos esenciales en México |
title_sort |
Sobreprecio y acceso a los medicamentos: el caso de los medicamentos esenciales en México |
author |
Molina-Salazar, Raúl E. |
author_facet |
Molina-Salazar, Raúl E. Rivas-Vilchis, José F. |
author_role |
author |
author2 |
Rivas-Vilchis, José F. |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Molina-Salazar, Raúl E. Rivas-Vilchis, José F. |
dc.subject.por.fl_str_mv |
Medicamentos Esenciales Precios de Medicamentos Políticas de Salud |
topic |
Medicamentos Esenciales Precios de Medicamentos Políticas de Salud |
description |
Accessibility and availability of drugs has been a matter of great concern for health services all over the world, especially for less developed countries. The World Health Organization has devoted considerable time to this matter. Although the essential drug policy has been well-accepted by health agencies and NGOs, the pharmaceutical industry has not proven willing to produce essential drugs at affordable prices. The purpose of this study is to examine price levels of essential drugs in Mexico. The evaluation was performed through a comparison of international and national prices for leading drugs in the respective therapeutic categories and included in the WHO model list of essential drugs. The study shows clearly that prices of essential brand-name drugs in Mexico are very high. Per capita consumption has remained stable despite a sharp decrease in the Mexican GDP since 1995. The article discusses the reasons for this and proposes measures to deal with the problem. |
publishDate |
1998 |
dc.date.none.fl_str_mv |
1998-07-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/996 |
url |
https://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/996 |
dc.language.iso.fl_str_mv |
spa |
language |
spa |
dc.relation.none.fl_str_mv |
https://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/996/1982 https://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/996/1983 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html application/pdf |
dc.publisher.none.fl_str_mv |
Reports in Public Health Cadernos de Saúde Pública |
publisher.none.fl_str_mv |
Reports in Public Health Cadernos de Saúde Pública |
dc.source.none.fl_str_mv |
Reports in Public Health; Vol. 14 No. 3 (1998): July/September Cadernos de Saúde Pública; v. 14 n. 3 (1998): Julho/Setembro 1678-4464 0102-311X reponame:Cadernos de Saúde Pública instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
Cadernos de Saúde Pública |
collection |
Cadernos de Saúde Pública |
repository.name.fl_str_mv |
Cadernos de Saúde Pública - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
cadernos@ensp.fiocruz.br||cadernos@ensp.fiocruz.br |
_version_ |
1798943344904110080 |